Commentary|Articles|May 5, 2026

Breast Cancer Experts Preview Abstracts to Watch at the 2026 ESMO Breast Cancer Congress

Experts in a range of breast cancer subtypes highlight research data being presented at the 2026 ESMO Breast Cancer Congress.

As we gear up for the 2026 European Society for Medical Oncology (ESMO) Breast Cancer Congress, taking place May 6 to 8, 2026, in Berlin, Germany, OncLive® asked leading breast oncologists to share the presentations and conversations at the top of their lists. We gathered exclusive insights from:

Related to this article

November 8th, 2026

Invikafusp alfa plus sacituzumab govitecan produced responses and disease control in metastatic TNBC and HR-positive/HER2-negative breast cancer.

November 6th, 2026

Experts break down key kidney cancer data and trends from the 2026 ESMO Congress.

November 5th, 2026

Experts break down key gynecologic cancer data and trends from the 2026 ESMO Congress.

November 4th, 2026

Lung cancer experts outline some of the most crucial findings from ESMO 2026 that could affect future clinical decision-making.

November 4th, 2026

Rocbrutinib plus chemoimmunotherapy led to complete responses in patients with untreated B-cell lymphomas.

November 3rd, 2026

See what leading breast oncologists have to say about practice-informing data to come out of the 2026 ESMO Congress.

October 29th, 2026

Breast cancer experts answer key questions on selecting, sequencing, and managing ADCs in HR-positive, HER2-positive, and triple-negative disease.

October 28th, 2026

Trastuzumab deruxtecan plus pertuzumab improved systemic and intracranial outcomes in HER2-positive breast cancer with baseline brain metastases.